MAPS Responds to FDA Progress on MDMA-Assisted PTSD Therapy
Denver, Colorado, USA — August 10, 2026 Multidisciplinary Association for Psychedelic Studies (MAPS) responded to reports that Resilient Pharmaceuticals,...
psychedelic medicine
Advertisement
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Clearmind Reports Positive Intranasal MEAI Results
Vancouver, Canada, July 16, 2026 Clearmind Medicine announced positive ex vivo results demonstrating enhanced nasal retention for its intranasal...
Optimi Health Launches Standardized Psilocybin Microdose Capsules for Clinical Research
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
Advertisements
PharmAla Supplies MDMA for PTSD Phase 2 Clinical Trial
TORONTO, Ontario, March 3, 2026 PharmAla Biotech Holdings Inc. has entered a supply and data agreement with Nautilus Sanctuary...
Advertisement
